Pharmaceutical trials with SGLT2i (8–10), GLP1-RA (26, 27), and finerenone (28) in participants with pre-existing CKD at high risk for progression also reported negative eGFR slopes in both treatment and placebo groups. The gene discussed is GLP1R; the disease is chronic kidney disease.